BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer

- Collaboration with Amgen to explore the clinical potential of Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amge...

April 03, 2026 | News

NJ Bio And Ajinomoto Bio-Pharma Services Collaborate To Expand AJICAP Access For ADC Development

NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"),...

April 02, 2026 | News

Bio Sourcing And Tiny Cargo Partner To Develop Oral Monoclonal Antibody Therapies Using Milk Derived Exosomes

Bio‑Sourcing SA (‘Bio-Sourcing’) and The Tiny Cargo Company (‘Tiny Cargo’) today announce a strategic collaboration to co‑devel...

March 31, 2026 | News

Biocytogen Partner NEOK Bio Secures FDA IND Clearance For NEOK002 ADC Program

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and developm...

March 30, 2026 | News

Akeso Advances IO 2.0 Plus ADC 2.0 Strategy With Phase II Trial Clearance In China

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that it has received clearance from the Center for Drug Evaluation (CDE) of China's ...

March 26, 2026 | News

WuXi XDC Reports Strong 2025 Growth Driven By Bioconjugate Leadership And Expanding Global Footprint

Revenue increased by 46.7% YoY to RMB 5,944 million Gross profit surged by 72.5% YoY to RMB 2,139 million, with its margin of 3...

March 25, 2026 | Company results

Kelun Biotech Reports Strong 2025 Performance With Expanding ADC Pipeline And Commercial Momentum

Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase...

March 25, 2026 | News

Alphamab Oncology IND For Dual Payload Bispecific ADC JSKN021 Accepted By China NMPA

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative du...

March 16, 2026 | News

Innovent Secures China Approval For Jaypirca In Previously Treated CLL And SLL

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

March 03, 2026 | News

Pfizer And Astellas Report Strong Phase III EV 304 Results For PADCEV Plus Pembrolizumab In MIBC

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with ove...

March 02, 2026 | News

Antengene And Junshi Biosciences Enter Clinical Collaboration To Advance ATG 037 And JS207 Combination In Solid Tumors

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, ...

February 26, 2026 | News

Astellas And Vir Biotechnology Forge Global Partnership To Advance VIR 5500 In Prostate Cancer

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commerci...

February 25, 2026 | News

CARsgen Therapeutics Advances Commercial CAR T Cell Manufacturing With Shanghai Strategic Partnership

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that through its in...

February 17, 2026 | News

AsymBio Builds Integrated End To End Platforms To Accelerate Biopharmaceutical Development

AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms span...

February 12, 2026 | News

Stay Connected